All Articles

Although the combination of bevacizumab and olaparib showed superior progression-free survival compared with bevacizumab plus placebo as upfront maintenance therapy in women with advanced ovarian cancer, the lack of an olaparib monotherapy comparator limits meaningful interpretation. Read More ›

The rate of overall survival was similar between nivolumab and either gemcitabine or pegylated liposomal doxorubicin in the open-label, randomized phase 3 NINJA clinical trial of patients with platinum-resistant ovarian cancer, but the overall duration of response was longer in the nivolumab arm. Read More ›

In the FORWARD II clinical trial, mirvetuximab soravtansine combined with carboplatin and bevacizumab induced an overall response rate of 83% in patients with recurrent platinum-sensitive ovarian cancer. Read More ›

Copay maximizer programs are replacing copay accumulator programs, and the trend toward increasing cost burden for patients continues. Read More ›

No one can say that 2020 has been an ordinary year, although for most of us, it started out in a fairly normal manner. For me, it meant celebrating the New Year, writing, and enjoying some occasional snow. My speaking engagements and travel began ramping up in January, February, and early March, which allowed me to meet with colleagues and clients at practices, hospitals, and conferences. Then, the COVID-19 pandemic hit, and the bottom dropped out of all our worlds. Read More ›

The COVID-19 pandemic has led to a massive boom in telehealth, according to Heidi Kocher, Esq, Partner, Liles Parker, PLLC, Plano, TX. When lockdowns began to be enforced around the world, providers needed to make rapid and unprecedented changes to the way they delivered care, and healthcare teams and patients alike were required to quickly adapt to telehealth and telemedicine. Read More ›

At the 2020 NCCN hematologic malignancies conference, Shaji Kumar, MD, Consultant and Professor of Medicine, Division of Hematology, Mayo Clinic Cancer Center, Rochester, MN, discussed the “bonanza of treatment regimens for multiple myeloma.” Read More ›

The approaches to the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma are evolving, including the sequencing of therapy and a possibly expanded role for minimal residual disease (MRD) status, said William G. Wierda, MD, PhD, Section Chief, Chronic Lymphocytic Leukemia, M.D. Anderson Cancer Center, Houston, TX, at the National Comprehensive Cancer Network (NCCN) 2020 Virtual Congress: hematologic malignancies. Read More ›

Although chimeric antigen receptor (CAR) T-cell therapy has been a life-saving treatment for some patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), additional therapies may be able to perform equally well in select patients, said Andrew D. Zelenetz, MD, PhD, Medical Director, Quality Informatics, Memorial Sloan Kettering Cancer Center, New York City, at the National Comprehensive Cancer Network (NCCN) 2020 Virtual Congress: hematologic malignancies. Read More ›

At the 2020 ASCO Quality Care Symposium, Jean Wright, MD, Director of Safety and Quality, Department of Radiation Oncology and Molecular Radiation Sciences, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Washington, DC, advocated for multidisciplinary teams that include the patient as part of the care team. Read More ›